Comparison of asymmetric (low morning-dose) and standard split-dose regimen of PEG plus bisacodyl for bowel preparation: A randomized controlled trial

Dig Liver Dis. 2019 Jun;51(6):837-842. doi: 10.1016/j.dld.2018.12.012. Epub 2018 Dec 28.

Abstract

Background: Reducing the morning dose of PEG solution may be a reliable strategy to improve the patient compliance of split-dose regimens without affecting efficacy of bowel cleansing.

Aims: to compare the efficacy for bowel cleansing of an asymmetric split-dose regimen (25% of the dose on the day of colonoscopy and 75% on the day before) with the standard split-dose regimen.

Methods: Outpatients were enrolled in a randomized, single-blind, non-inferiority clinical trial. All subjects received a split-dose preparation with a 2L PEG-citrate-simethicone plus Bisacodyl. Patients were randomly assigned to: group A, asymmetric split-dose regimen; group B, symmetric split-dose regimen. Primary endpoint was the proportion of adequate bowel cleansing.

Results: Split-dose was taken by 81 and 80 patients in group A and B. Adequate bowel cleansing was achieved in 92.6% and 92.5% patients in group A and B (p = 1.000). No differences were observed regarding Boston Bowel Preparation Scale total score, adenoma detection rate and scores of each colon segment.

Conclusions: The reduction of morning dose of PEG in a split-dose regimen is not inferior to the standard split-dose regimen in achieving an adequate bowel cleansing. However, further studies are needed to evaluate whether asymmetric preparation is associated to a higher tolerability compared to symmetric split-dose regimen. (NCT03146052).

Keywords: Bowel preparation; Colonoscopy; Endoscopy; Polyethylene glycol; Screening.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Bisacodyl / administration & dosage*
  • Bisacodyl / adverse effects
  • Cathartics / administration & dosage*
  • Cathartics / adverse effects
  • Citric Acid / administration & dosage
  • Colon / drug effects*
  • Colonoscopy / standards*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Patient Compliance
  • Polyethylene Glycols / administration & dosage*
  • Polyethylene Glycols / adverse effects
  • Simethicone / administration & dosage
  • Single-Blind Method

Substances

  • Cathartics
  • Bisacodyl
  • Citric Acid
  • Polyethylene Glycols
  • Simethicone

Associated data

  • ClinicalTrials.gov/NCT03146052